These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 17956893)

  • 1. Cinacalcet's effect on the pharmacokinetics of tacrolimus, cyclosporine and mycophenolate in renal transplant recipients.
    Falck P; Vethe NT; Asberg A; Midtvedt K; Bergan S; Reubsaet JL; Holdaas H
    Nephrol Dial Transplant; 2008 Mar; 23(3):1048-53. PubMed ID: 17956893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oseltamivir, an influenza neuraminidase inhibitor drug, does not affect the steady-state pharmacokinetic characteristics of cyclosporine, mycophenolate, or tacrolimus in adult renal transplant patients.
    Lam H; Jeffery J; Sitar DS; Aoki FY
    Ther Drug Monit; 2011 Dec; 33(6):699-704. PubMed ID: 22105586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings.
    Zucker K; Rosen A; Tsaroucha A; de Faria L; Roth D; Ciancio G; Esquenazi V; Burke G; Tzakis A; Miller J
    Transpl Immunol; 1997 Sep; 5(3):225-32. PubMed ID: 9402690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of calcineurin inhibitors on pharmacokinetics of mycophenolic acid and its glucuronide metabolite during the maintenance period following renal transplantation.
    Naito T; Shinno K; Maeda T; Kagawa Y; Hashimoto H; Otsuka A; Takayama T; Ushiyama T; Suzuki K; Ozono S
    Biol Pharm Bull; 2006 Feb; 29(2):275-80. PubMed ID: 16462031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modelling.
    Cremers S; Schoemaker R; Scholten E; den Hartigh J; König-Quartel J; van Kan E; Paul L; de Fijter J
    Br J Clin Pharmacol; 2005 Sep; 60(3):249-56. PubMed ID: 16120063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronopharmacokinetics of mycophenolic acid and its glucuronide and acyl glucuronide metabolites in kidney transplant recipients converted from cyclosporine to everolimus.
    Tedesco-Silva H; Felipe CR; Slade A; Schmouder RL; Medina Pestana JO
    Ther Drug Monit; 2012 Dec; 34(6):652-9. PubMed ID: 23131696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of cyclosporine on steady-state pharmacokinetics of MPA in renal transplant recipients is not affected by the MPA formulation: analysis based on therapeutic drug monitoring data.
    Trkulja V; Lalić Z; Nađ-Škegro S; Lebo A; Granić P; Lovrić M; Pasini J; Božina N
    Ther Drug Monit; 2014 Aug; 36(4):456-64. PubMed ID: 24518562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug interaction between mycophenolate mofetil and tacrolimus detectable within therapeutic mycophenolic acid monitoring in renal transplant patients.
    Hübner GI; Eismann R; Sziegoleit W
    Ther Drug Monit; 1999 Oct; 21(5):536-9. PubMed ID: 10519451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclosporine A and tacrolimus combined with enteric-coated mycophenolate sodium influence the plasma mycophenolic acid concentration - a randomised controlled trial in Chinese live related donor kidney transplant recipients.
    Huang HF; Yao X; Chen Y; Xie WQ; Shen-Tu JZ; Chen JH
    Int J Clin Pract Suppl; 2014 Apr; (181):4-9. PubMed ID: 24673713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Best single time points to predict the area-under-the-curve in long-term heart transplant patients taking mycophenolate mofetil in combination with cyclosporine or tacrolimus.
    Mardigyan V; Giannetti N; Cecere R; Besner JG; Cantarovich M
    J Heart Lung Transplant; 2005 Oct; 24(10):1614-8. PubMed ID: 16210138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year.
    Ciancio G; Burke GW; Gaynor JJ; Mattiazzi A; Roth D; Kupin W; Nicolas M; Ruiz P; Rosen A; Miller J
    Transplantation; 2004 Jan; 77(2):244-51. PubMed ID: 14742989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and validation of limited sampling strategies for tacrolimus and mycophenolate in steroid-free renal transplant regimens.
    Poulin E; Greanya ED; Partovi N; Shapiro RJ; Al-Khatib M; Ensom MH
    Ther Drug Monit; 2011 Feb; 33(1):50-5. PubMed ID: 21157401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Steady-state pharmacokinetics of mycophenolic acid in renal transplant patients: exploratory analysis of the effects of cyclosporine, recipients' and donors' ABCC2 gene variants, and their interactions.
    Božina N; Lalić Z; Nađ-Škegro S; Borić-Bilušić A; Božina T; Kaštelan Ž; Trkulja V
    Eur J Clin Pharmacol; 2017 Sep; 73(9):1129-1140. PubMed ID: 28624888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant.
    Pawinski T; Durlik M; Szlaska I; Urbanowicz A; Majchrnak J; Gralak B
    J Clin Pharm Ther; 2006 Feb; 31(1):27-34. PubMed ID: 16476117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of mycophenolic acid in Chinese kidney transplant patients.
    Lu XY; Huang HF; Sheng-Tu JZ; Liu J
    J Zhejiang Univ Sci B; 2005 Sep; 6(9):885-91. PubMed ID: 16130190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New concepts in cyclosporine pharmacokinetic and dynamic monitoring: the impact of concomitant immunosuppression on target C2 concentrations.
    Brunet M; Millán O; Jiménez O; Campistol JM; Vidal E; Rojo I; Oppenheimer F; Fortuna V; Martorell J
    Transplant Proc; 2004 Mar; 36(2 Suppl):437S-441S. PubMed ID: 15041382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Different effect of cyclosporine and tacrolimus on renal expression of P-glycoprotein in human kidney transplantation.
    Yu X; Zhang B; Xing C; Sun B; Liu M; Zhang W; Gu M
    Transplant Proc; 2008 Dec; 40(10):3455-9. PubMed ID: 19100412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: results at three years.
    Gonwa T; Johnson C; Ahsan N; Alfrey EJ; Halloran P; Stegall M; Hardy M; Metzger R; Shield C; Rocher L; Scandling J; Sorensen J; Mulloy L; Light J; Corwin C; Danovitch G; Wachs M; VanVeldhuisen P; Leonhardt M; Fitzsimmons WE
    Transplantation; 2003 Jun; 75(12):2048-53. PubMed ID: 12829910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of mycophenolate mofetil in Omani patients on cyclosporine or tacrolimus.
    Mohsin N; Al-Raisi F; Militsala E; Kamble P; Abdel Razek E; Baddruddin M
    Transplant Proc; 2015 May; 47(4):1122-4. PubMed ID: 26036534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A simultaneous d-optimal designed study for population pharmacokinetic analyses of mycophenolic Acid and tacrolimus early after renal transplantation.
    Musuamba FT; Mourad M; Haufroid V; Demeyer M; Capron A; Delattre IK; Delaruelle F; Wallemacq P; Verbeeck RK
    J Clin Pharmacol; 2012 Dec; 52(12):1833-43. PubMed ID: 22207766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.